Search This Blog

Thursday, December 19, 2019

Amarin down 2% premarket on bearish report

Amarin (NASDAQ:AMRN) slips 2% premarket on light volume on the heels of a cautious report from Medical Research Collaborative who questions the robustness of Vascepa’s intellectual property.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)